25 June 2025: A major ophthalmology survey of 35 US surgeons conducted by Needham shows:
- iTrack Advance expected to gain the most MIGS share (+100 bps)
- MIGS market growing faster than any other segment, with EYE outpacing all peers
- Glaukos' iStent forecast to lose the most share (-180 bps), signaling the move away from stents and towards more effective procedures such as canaloplasty
- EYE the only MIGS company gaining clear share from Omni.
Nova Eye leading MIGS momentum according to US ophthalmology survey!
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
15.0¢ |
Change
0.008(5.26%) |
Mkt cap ! $42.70M | |||
| Open | High | Low | Value | Volume |
| 14.5¢ | 15.0¢ | 14.0¢ | $95.46K | 655.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99000 | 14.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.0¢ | 426306 | 6 |
View Market Depth
| Last trade - 16.10pm 15/09/2025 (20 minute delay) ? |
| EYE (ASX) Chart |